Takala, Jaana http://orcid.org/0000-0001-8753-3341
Vähätalo, Iida http://orcid.org/0000-0003-0962-8446
Tuomisto, Leena E. http://orcid.org/0000-0001-6990-4508
Niemelä, Onni
Ilmarinen, Pinja
Kankaanranta, Hannu
Article History
Received: 13 July 2023
Accepted: 27 February 2024
First Online: 9 March 2024
Competing interests
: None of the authors declares any competing interests concerning this article. J.T. reports personal fees from NovoNordisk, Novartis, AstraZeneca, and Sanofi outside the current work. I.V. reports personal fees from AstraZeneca outside the current work. L.E.T. reports personal fees from GSK and Boehringer-Ingelheim outside the current work. P.I. is employed by GSK as scientific advisor. H.K. reports fees for consultancies and lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, Covis Pharma, GSK, Medscape, MSD, Novartis, Orion Pharma and SanofiGenzyme outside the current work. O.N. declares that he has no relevant conflicts of interest.